Savara to report second quarter 2020 financial results and provide business update

Austin, texas--(business wire)--savara inc. (nasdaq: svra), an orphan lung disease company, today announced that the company will report second quarter 2020 financial results and provide a business update on thursday, august 6, 2020. savara management will host a conference call/webcast at 4:30 p.m. eastern time (et)/1:30 p.m. pacific time (pt). shareholders and other interested parties may access the call by dialing (855) 239-3120 from the u.s., (855) 669-9657 from canada, and (412) 542-4127 from elsewhere outside the u.s. and requesting the “savara inc.” call. a live webcast of the call can be accessed on the investors page of savara’s website at https://www.savarapharma.com/investors/events-presentations/. approximately one hour after the call, a telephone replay will be available and will remain available through august 13, 2020 by dialing (877) 344-7529 from the u.s., (855) 669-9658 from canada and (412) 317-0088 from elsewhere outside the u.s. and entering the replay access code 10146176. a webcast replay will be available on the investors page of savara’s website and will remain available for 30 days. about savara savara is an orphan lung disease company with a pipeline comprised of three investigational compounds, all of which use an inhaled delivery route. our lead program, molgradex, is an inhaled granulocyte-macrophage colony-stimulating factor (gm-csf) in phase 3 development for autoimmune pulmonary alveolar proteinosis (apap) and in phase 2a development for nontuberculous mycobacterial (ntm) lung infection in both non-cystic fibrosis and cystic fibrosis-affected individuals. apulmiq is an inhaled ciprofloxacin in phase 3 development for non-cystic fibrosis bronchiectasis (ncfb). aerovanc is an inhaled vancomycin in phase 3 development for persistent methicillin-resistant staphylococcus aureus (mrsa) lung infection in people living with cystic fibrosis. savara’s strategy involves broadening its pipeline through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. our management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approval and commercialization. more information can be found at www.savarapharma.com. (twitter: @savarapharma, linkedin: www.linkedin.com/company/savara-pharmaceuticals/).
SVRA Ratings Summary
SVRA Quant Ranking